O., Scherr, J
De Marinis YZ, Salehi A, Ward CE, Zhang Q, Abdulkader F, Bengtsson M, Braha O, Braun M, Ramracheya R, Amisten S, Habib AM, Moritoh Y, Zang E, Reimann F, Rosengren AH, Shibasaki T, Gribble F, Renstrm E, Seino S, Eliasson L, Rorsman P: GLP-1 inhibits and adrenaline stimulates glucagon release by differential modulation of N- and L-type Ca2+ channel-dependent exocytosis
There are several GLP-1RAs and one GIP/GLP-1RA available for the management of T2DM and/or obesity
Insurance companies have increasingly cut back on coverage for GLP-1 drugs, such as Wegovy and Ozempic
Research published in respected peer-reviewed journals has indicated that a substantial portion of the weight lost during GLP-1 therapy may derive from lean body mass instead of fat exclusively